These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27741127)

  • 1. Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes.
    Garrouste C; Anglicheau D; Kamar N; Bachelier C; Rivalan J; Pereira B; Caillard S; Aniort J; Gatault P; Soubrier M; Sayegh J; Colosio C; Buisson A; Thervet E; Bouvier N; Heng AE
    Medicine (Baltimore); 2016 Oct; 95(41):e5108. PubMed ID: 27741127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Tumor Necrosis Factor α Inhibitor Therapy After Renal Transplantation: A Comparative Analysis and Associated Outcomes.
    Quinn CS; Jorgenson MR; Descourouez JL; Muth BL; Astor BC; Mandelbrot DA
    Ann Pharmacother; 2019 Mar; 53(3):268-275. PubMed ID: 30234366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
    Wojciechowski D; Chandran S; Vincenti F
    Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors?
    Pascher A; Klupp J
    BioDrugs; 2005; 19(4):211-31. PubMed ID: 16128605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of two different antithymocyte globulins used in induction therapy in kidney transplant recipients: A single-center experience.
    Styrc B; Sobolewski M; Chudek J; Kolonko A; Więcek A
    Clin Transplant; 2019 Oct; 33(10):e13680. PubMed ID: 31365162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypogammaglobulinemia and risk of severe infection in kidney transplant recipients.
    Augusto JF; Garnier AS; Demiselle J; Langs V; Picquet J; Legall R; Sargentini C; Culty T; Poli C; Ammi M; Ducancelle A; Chevailler A; Duveau A; Subra JF; Sayegh J
    Transpl Infect Dis; 2016 Oct; 18(5):741-751. PubMed ID: 27509578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of Antithymocyte Globulin (Rabbit) to Treat a Severe, Mixed Rejection Episode in a Pregnant Renal Transplant Recipient.
    Kutzler HL; Ye X; Rochon C; Martin ST
    Pharmacotherapy; 2016 Apr; 36(4):e18-22. PubMed ID: 26892892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever.
    Trabulus S; Korkmaz M; Kaya E; Seyahi N
    Clin Transplant; 2018 Aug; 32(8):e13345. PubMed ID: 29981275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney allograft failure in the steroid-free immunosuppression era: A matched case-control study.
    Alkadi MM; Kim J; Aull MJ; Schwartz JE; Lee JR; Watkins A; Lee JB; Dadhania DM; Seshan SV; Serur D; Kapur S; Suthanthiran M; Hartono C; Muthukumar T
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28921709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Pathologic Features and Graft Outcomes of Rejection on Kidney Transplant.
    Park WY; Paek JH; Jin K; Park SB; Choe M; Han S
    Transplant Proc; 2019 Oct; 51(8):2655-2659. PubMed ID: 31345597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
    Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
    Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
    Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
    PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent AA Amyloidosis Combined With Chronic Active Antibody-mediated Rejection After Kidney Transplantation.
    Yeo MK; Ham YR; Choi SY; Lee YM; Park MH; Suh KS
    Iran J Kidney Dis; 2017 Jul; 11(4):322-325. PubMed ID: 28794296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.
    Waljee AK; Higgins PDR; Jensen CB; Villumsen M; Cohen-Mekelburg SA; Wallace BI; Berinstein JA; Allin KH; Jess T
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):276-284. PubMed ID: 31836320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.